Abstract:
An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject.
Abstract:
An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.
Abstract:
A method of preventing and/or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.
Abstract:
A method of selecting a subject for administration of an anti-c-Met antibody, comprising (i) determining the presence or the amount of a ubiquitin peptidase, (ii) determining the presence or expression level of a ubiquitin peptidase coding gene, or (iii) measuring the activity of a ubiquitin peptidase, in a biological sample; as well as related methods.
Abstract:
A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.